Pancragen is a synthetic Khavinson tetrapeptide (Lys‑Glu‑Asp‑Trp) marketed for pancreatic and metabolic support, derived from early Russian research that remains preliminary. In community practice, clinicians generally administer 20 mg subcutaneously each day; timing and cycling are not standardized, and the dose is taken continuously unless a practitioner advises a break. The primary trade‑off is the absence of any FDA‑approved indication, meaning all human use is off‑label or compounded, and injection‑site reactions have not emerged as a consistent theme in user reports.
Data last updated
Measured on 2 of 6 axes
Evidence shape
Pancragen currently exists as an animal-only research peptide with no published human clinical trials. The existing literature is restricted to preclinical and mechanistic studies, providing no data on safety or efficacy in human subjects. Because there are zero registered trials and no completed human studies, the evidence base remains entirely theoretical and lacks the necessary validation to support clinical application.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Symptom-relevant clinical or community evidence has not been captured for this peptide yet.
price offers can be sorted by column
How Pancragen is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
The clinician tier lists a 20 mg subcutaneous dose of Pancragen, but does not specify how often it should be given or any cycle length.
No structured protocol details captured for this tier yet.